File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.currproblcancer.2024.101076
- Scopus: eid_2-s2.0-85188816803
- PMID: 38537395
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Efficacy and safety of selinexor for patients with relapsed and refractory multiple myeloma: A meta-analysis
Title | Efficacy and safety of selinexor for patients with relapsed and refractory multiple myeloma: A meta-analysis |
---|---|
Authors | |
Keywords | Meta-analysis Multiple myeloma [MesH] Selinexor [Mesh] SINE compounds |
Issue Date | 26-Mar-2024 |
Publisher | Elsevier |
Citation | Current Problems in Cancer, 2024, v. 50 How to Cite? |
Abstract | Purpose: Selinexor is a first-in-class, oral selective-inhibitor-of-nuclear-export, granted accelerated approval by FDA (2019) for relapsed and refractory multiple myeloma (RRMM). We sought to quantitatively summarize the selinexor efficacy and safety in RRMM. Methods: We searched PubMed, EMBASE, CENTRAL, clinicaltrial.gov, and google scholar, until May 2023, studies about selinexor use in RRMM. The outcome measures of interest were primarily efficacy outcomes, in addition to safety outcomes. Random-effect model analyses were performed, at statistical significance of P<0.05, using the RevMan software. Results: Meta-analyses of eleven included clinical trials yielded a significant 56.21% overall clinical benefit, 46.91% overall response, 4.89% complete response, 23.41% very good partial response, 24.68% partial response, and 28.06% stable disease rates with selinexor. Due to safety reasons, selinexor caused significant increase in discontinuation rate, 16.80%. Subgroup analyses demonstrated higher efficacy with selinexor plus dexamethasone and proteasome inhibitor combinations than with selinexor alone. The multiple myeloma type, high cytogenetic risk, refractory state, and advanced disease state did not affect performance. Risk of selection, performance, and detection biases were unclear in the included trials. Conclusion: Selinexor led to significant positive responses with an acceptable safety profile in RRMM patients, despite higher rates of safety-related discontinuations. Selinexor-based combinations further enhanced response. |
Persistent Identifier | http://hdl.handle.net/10722/348737 |
ISSN | 2023 Impact Factor: 2.5 2023 SCImago Journal Rankings: 0.759 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Shafei, Laila | - |
dc.contributor.author | Bashir, Shaima | - |
dc.contributor.author | Chan, Esther W | - |
dc.contributor.author | Abushanab, Dina | - |
dc.contributor.author | Hamad, Anas | - |
dc.contributor.author | Al-Badriyeh, Daoud | - |
dc.date.accessioned | 2024-10-15T00:30:31Z | - |
dc.date.available | 2024-10-15T00:30:31Z | - |
dc.date.issued | 2024-03-26 | - |
dc.identifier.citation | Current Problems in Cancer, 2024, v. 50 | - |
dc.identifier.issn | 0147-0272 | - |
dc.identifier.uri | http://hdl.handle.net/10722/348737 | - |
dc.description.abstract | Purpose: Selinexor is a first-in-class, oral selective-inhibitor-of-nuclear-export, granted accelerated approval by FDA (2019) for relapsed and refractory multiple myeloma (RRMM). We sought to quantitatively summarize the selinexor efficacy and safety in RRMM. Methods: We searched PubMed, EMBASE, CENTRAL, clinicaltrial.gov, and google scholar, until May 2023, studies about selinexor use in RRMM. The outcome measures of interest were primarily efficacy outcomes, in addition to safety outcomes. Random-effect model analyses were performed, at statistical significance of P<0.05, using the RevMan software. Results: Meta-analyses of eleven included clinical trials yielded a significant 56.21% overall clinical benefit, 46.91% overall response, 4.89% complete response, 23.41% very good partial response, 24.68% partial response, and 28.06% stable disease rates with selinexor. Due to safety reasons, selinexor caused significant increase in discontinuation rate, 16.80%. Subgroup analyses demonstrated higher efficacy with selinexor plus dexamethasone and proteasome inhibitor combinations than with selinexor alone. The multiple myeloma type, high cytogenetic risk, refractory state, and advanced disease state did not affect performance. Risk of selection, performance, and detection biases were unclear in the included trials. Conclusion: Selinexor led to significant positive responses with an acceptable safety profile in RRMM patients, despite higher rates of safety-related discontinuations. Selinexor-based combinations further enhanced response. | - |
dc.language | eng | - |
dc.publisher | Elsevier | - |
dc.relation.ispartof | Current Problems in Cancer | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | Meta-analysis | - |
dc.subject | Multiple myeloma [MesH] | - |
dc.subject | Selinexor [Mesh] | - |
dc.subject | SINE compounds | - |
dc.title | Efficacy and safety of selinexor for patients with relapsed and refractory multiple myeloma: A meta-analysis | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.currproblcancer.2024.101076 | - |
dc.identifier.pmid | 38537395 | - |
dc.identifier.scopus | eid_2-s2.0-85188816803 | - |
dc.identifier.volume | 50 | - |
dc.identifier.eissn | 1535-6345 | - |
dc.identifier.issnl | 0147-0272 | - |